Mitchell Mcleod Pugh & Williams Inc. cut its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 2.5% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,589 shares of the company’s stock after selling 169 shares during the quarter. Eli Lilly and Company comprises about 1.4% of Mitchell Mcleod Pugh & Williams Inc.’s portfolio, making the stock its 12th biggest holding. Mitchell Mcleod Pugh & Williams Inc.’s holdings in Eli Lilly and Company were worth $5,966,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in LLY. Independent Advisor Alliance increased its holdings in shares of Eli Lilly and Company by 1.7% during the fourth quarter. Independent Advisor Alliance now owns 32,269 shares of the company’s stock worth $18,810,000 after purchasing an additional 544 shares during the period. Apexium Financial LP increased its stake in Eli Lilly and Company by 1,819.1% during the 4th quarter. Apexium Financial LP now owns 11,438 shares of the company’s stock worth $6,667,000 after acquiring an additional 10,842 shares during the period. Capital Planning LLC acquired a new position in Eli Lilly and Company in the 1st quarter valued at $262,000. CHURCHILL MANAGEMENT Corp bought a new stake in shares of Eli Lilly and Company during the 1st quarter valued at $6,916,000. Finally, M&G Plc bought a new stake in shares of Eli Lilly and Company during the 1st quarter valued at $8,896,000. 82.53% of the stock is owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other news, EVP Johna Norton sold 7,056 shares of the stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $819.38, for a total value of $5,781,545.28. Following the completion of the sale, the executive vice president now owns 25,428 shares of the company’s stock, valued at $20,835,194.64. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, EVP Johna Norton sold 7,056 shares of the stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $819.38, for a total value of $5,781,545.28. Following the completion of the sale, the executive vice president now owns 25,428 shares of the company’s stock, valued at $20,835,194.64. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total value of $197,362,200.00. Following the completion of the sale, the insider now directly owns 96,943,810 shares of the company’s stock, valued at approximately $91,109,731,514.20. The disclosure for this sale can be found here. Insiders sold a total of 1,097,883 shares of company stock valued at $972,022,568 in the last 90 days. Corporate insiders own 0.13% of the company’s stock.
Analysts Set New Price Targets
Check Out Our Latest Report on Eli Lilly and Company
Eli Lilly and Company Price Performance
LLY traded up $19.82 on Friday, reaching $960.02. The stock had a trading volume of 2,555,073 shares, compared to its average volume of 3,625,430. Eli Lilly and Company has a fifty-two week low of $516.57 and a fifty-two week high of $972.53. The firm has a 50-day moving average of $892.64 and a 200-day moving average of $822.08. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. The company has a market capitalization of $912.43 billion, a price-to-earnings ratio of 141.39, a price-to-earnings-growth ratio of 2.91 and a beta of 0.41.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The business had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 16.51 EPS for the current year.
Eli Lilly and Company Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be issued a $1.30 dividend. The ex-dividend date is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.54%. Eli Lilly and Company’s payout ratio is presently 76.58%.
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
See Also
- Five stocks we like better than Eli Lilly and Company
- EV Stocks and How to Profit from Them
- Don’t Overlook Campbell Soup: Here’s What Could Drive Its Stock
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win
- The 3 Best Fintech Stocks to Buy Now
- Veeva’s Stock Jumps on Stellar Q2 Results—Don’t Miss Out
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.